Intestinal HDL transported via the portal vein protected against liver injury in mice by sequestering bacterial lipopolysaccharide, and drugs elevating intestinal HDL improved disease outcomes.
Does intestinal HDL protect against liver injury?
Intestinal HDL3 protects the liver from injury by sequestering gut-derived bacterial lipopolysaccharide in the portal vein, suggesting a novel therapeutic target for liver disease.
Intestinal HDL is hepatoprotective High-density lipoprotein (HDL) is important for cholesterol metabolism and may have anti-inflammatory and antimicrobial properties. Although HDL is mainly produced by the liver, the intestine is also a source. Han et al. show in mice that intestinal HDL is not routed to the systemic circulation. Rather, in the form of HDL3, it is directly transported to the liver through the hepatic portal vein. There, it sequesters bacterial lipopolysaccharide from the gut that can trigger inflammation and liver damage. In various models of liver injury, loss of enteric HDL exacerbated pathology. By contrast, drugs elevating intestinal HDL improved disease outcomes. HDL3 is enriched in human portal venous blood, suggesting that enteric HDL may be targetable for the treatment of liver disease. Science , abe6729, this issue p. eabe6729
Han et al. (Thu,) conducted a other in Liver injury. Enteric HDL vs. Loss of enteric HDL was evaluated on Liver pathology and inflammation. Intestinal HDL transported via the portal vein protected against liver injury in mice by sequestering bacterial lipopolysaccharide, and drugs elevating intestinal HDL improved disease outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: